多发性硬化进展:是时候采用新的机制驱动框架了
本文提出多发性硬化的临床病程不应再按复发缓解型、继发进展型和原发进展型等离散描述符 categorise,而应视为由重叠的病理与修复/代偿过程相对贡献所定义的连续谱。进展的表观演变反映了从局灶性急性损伤向广泛炎症和神经退行性变的部分转变,并伴有神经可塑性和髓鞘再生等代偿机制失败;衰老增加神经易感性并降低恢复力。对进展关键机制的新理解及量化进展性病理的措施可能对临床照护、治疗目标和监管决策产生重要有益影响。
要点
- 多发性硬化临床病程宜视为连续谱,而非离散的复发缓解型、继发进展型和原发进展型。
- 进展的表观演变反映从局灶急性损伤向广泛炎症和神经退行性变的部分转变,伴代偿机制失败。
- 衰老增加神经损伤易感性并降低恢复力,个体间和随时间变化的病理过程共同贡献病程。
核心结论
- 多发性硬化的临床病程最好视为连续谱,由重叠的病理和修复或代偿过程的相对贡献定义。
- 对进展关键机制的新理解和量化进展性病理的措施可能对临床照护、治疗目标和监管决策产生重要有益影响。
研究设计与样本
- 本文为Lancet Neurol发表的综述,未报告系统检索范围、数据库、检索时限或纳入研究数量。
主要发现
- 累积证据提示多发性硬化的临床病程最好视为连续谱,其贡献来自并存的病理生理过程,这些过程因个体和随时间而变化。
- 向进展性病程的表观演变反映了从以局灶性急性损伤为主向广泛炎症和神经退行性变的部分转变,并伴有神经可塑性和髓鞘再生等代偿机制的失败。
- 衰老增加神经对损伤的易感性并降低恢复力。
关键数值与推荐
- 传统上多发性硬化按复发缓解型、继发进展型和原发进展型等离散临床描述符分类,用于患者照护、研究和药物监管批准。
- 新考虑将多发性硬化病程视为由重叠的病理和修复或代偿过程相对贡献定义的光谱。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors-relapsing-remitting, secondary progressive, and primary progressive-for patient care, research, and regulatory approval of medications. Accumulating evidence suggests that the clinical course of multiple sclerosis is better considered as a continuum, with contributions from concurrent pathophysiological processes that vary across individuals and over time. The apparent evolution to a progressive course reflects a partial shift from predominantly localised acute injury to widespread inflammation and neurodegeneration, coupled with failure of compensatory mechanisms, such as neuroplasticity and remyelination. Ageing increases neural susceptibility to injury and decreases resilience. These observations encourage a new consideration of the course of multiple sclerosis as a spectrum defined by the relative contributions of overlapping pathological and reparative or compensatory processes. New understanding of key mechanisms underlying progression and measures to quantify progressive pathology will potentially have important and beneficial implications for clinical care, treatment targets, and regulatory decision-making.
引用
- Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2022. PMID: 36410373. doi:10.1016/S1474-4422(22)00289-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。